ISM-6331
- Generic Name
- ISM-6331
Insilico's AI-Designed Gut-Restricted PHD Inhibitor, ISM5411, Shows Promise in Phase I IBD Trials
• Insilico Medicine's ISM5411, an AI-designed gut-restricted PHD inhibitor, demonstrates favorable safety and tolerability in Phase I trials for inflammatory bowel disease (IBD).
• The trials validate ISM5411's gut-restrictive properties, showing minimal systemic exposure and a high fecal/plasma ratio, potentially reducing systemic side effects.
• Insilico plans to advance ISM5411 to a Phase II proof-of-concept study in active ulcerative colitis patients in the second half of 2025.
• The rapid development of ISM5411, facilitated by Insilico's Chemistry42 AI platform, highlights the potential of AI in accelerating drug discovery and development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath